Your Prognosis Two Weeks Post-Discharge
Your prognosis is excellent—with continued adherence to your anticoagulation regimen, you have a very low risk of recurrent PE or death over the next 30-90 days, and your long-term outlook depends primarily on whether your PE had an identifiable reversible cause. 1
Immediate Short-Term Outlook (Next 30-90 Days)
Since you remain hemodynamically stable two weeks after discharge and are taking your medications as prescribed, your risk of complications is now very low:
- Recurrent VTE risk while on anticoagulation: Approximately 1.4 per 100 person-years (essentially <2% annually) 1
- 30-day mortality risk: Near zero if you've remained stable without deterioration 2
- Risk of clinical decompensation: Only 1.4-2.9% if your heart rate, blood pressure, and cardiac biomarkers normalized within the first 48 hours after starting treatment 2
The critical window has passed. Most patients with intermediate-risk PE who deteriorate do so within the first 72 hours to 7 days 3. Since you're two weeks out and stable, you've successfully navigated the highest-risk period.
What Determines Your Long-Term Prognosis
Your long-term outlook hinges on what caused your PE in the first place 1:
If Your PE Had a Major Reversible Risk Factor
(Surgery >30 minutes, hospitalization ≥3 days confined to bed, cesarean section, lower limb fracture)
- Annual recurrence risk after stopping anticoagulation: <3% per year 4
- Recommendation: You can safely stop anticoagulation after 3-6 months of treatment 1
- Your prognosis: Excellent—essentially return to baseline risk
If Your PE Had NO Identifiable Risk Factor (Unprovoked)
- Annual recurrence risk after stopping anticoagulation: 30-40% over 10 years 1
- Recommendation: Continue anticoagulation indefinitely (extended phase) 1
- With continued anticoagulation: Risk of recurrent VTE drops to ~1.4 per 100 person-years 1
- Your prognosis: Excellent while on anticoagulation; high recurrence risk if stopped
If Your PE Had a Minor Reversible Risk Factor
(Surgery <30 minutes, brief hospitalization, estrogen therapy, peripartum period)
- Annual recurrence risk: 4.2-7.1% per year 1
- Recommendation: Shared decision-making about continuing vs. stopping at 3-6 months 1
- Your prognosis: Intermediate—requires individualized assessment of bleeding vs. clotting risk
Optimizing Your Medication for Long-Term Safety
If you continue anticoagulation beyond 6 months, switching to half-dose therapy significantly reduces bleeding risk without compromising protection 1:
- Rivaroxaban: Reduce from 20 mg daily to 10 mg daily
- Apixaban: Reduce from 5 mg twice daily to 2.5 mg twice daily 5
This approach reduces clinically relevant bleeding by 39% (from 15.2% to 9.9%) while maintaining similar protection against recurrent clots 1. The 2026 AHA/ACC guidelines give this a Class 1A recommendation—the strongest level of evidence 1.
What to Watch For
Red Flags Requiring Immediate Evaluation
- New or worsening shortness of breath
- Chest pain
- Coughing up blood
- Leg swelling or pain
- Lightheadedness or fainting
Expected Recovery Timeline
- Most patients: Gradual improvement in exercise tolerance over 3-6 months
- Persistent symptoms beyond 3 months: Occurs in up to 50% of survivors and warrants formal evaluation for chronic thromboembolic disease 6
Your 3-Month Checkpoint
You should have a structured follow-up visit at approximately 3 months 4, 6. This visit should:
- Reassess symptoms: Persistent dyspnea or exercise limitation needs investigation
- Determine anticoagulation duration: Based on your risk factor category
- Screen for complications: Echocardiography and possibly ventilation/perfusion scan if symptomatic
- Evaluate for chronic thromboembolic pulmonary hypertension (CTEPH): Develops in 2-3% of PE survivors 6
The Bottom Line
You're doing well. The fact that you're two weeks out, stable, and adherent to therapy means you've cleared the most dangerous period. Your specific long-term prognosis depends on whether your PE was provoked by a reversible factor—this determines whether you'll need lifelong anticoagulation or can safely stop after 3-6 months. Either way, with proper management, your outlook is favorable. The key now is maintaining medication adherence and attending your 3-month follow-up to finalize your long-term treatment plan.